Patents by Inventor Diana Blithe
Diana Blithe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227492Abstract: Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogenic, androgenic, and estrogenic activity, which can prevent or inhibit bone density loss in subjects. Oligomeric compound embodiments disclosed herein provide the ability to control receptor activation and/or treatment by incorporating a tunable linker group which couples steroidal-based compounds to one another or with therapeutic agents and facilitates selective cleavage of the monomeric components of the oligomeric compound.Type: ApplicationFiled: June 10, 2021Publication date: July 20, 2023Applicants: The USA as represented by the Secretary, Department of Health and Human Services, Ash Stevens, LLCInventors: Min Lee, Diana Blithe, Ming-Teh Lin, Pranab Gupta, Bashir Kaskar
-
Patent number: 10772897Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: GrantFiled: December 21, 2018Date of Patent: September 15, 2020Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Publication number: 20190209583Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: ApplicationFiled: December 21, 2018Publication date: July 11, 2019Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Patent number: 10159681Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: GrantFiled: February 5, 2016Date of Patent: December 25, 2018Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Publication number: 20170246189Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl) -19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: May 16, 2017Publication date: August 31, 2017Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Patent number: 9682088Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: GrantFiled: October 1, 2015Date of Patent: June 20, 2017Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Patent number: 9616073Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: GrantFiled: April 13, 2010Date of Patent: April 11, 2017Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Lynnette Nieman, Diana Blithe
-
Publication number: 20160317555Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: ApplicationFiled: February 5, 2016Publication date: November 3, 2016Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Patent number: 9283233Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: GrantFiled: March 2, 2015Date of Patent: March 15, 2016Assignees: LABORATOIRE HRA-PHARMA, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Publication number: 20160022698Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: October 1, 2015Publication date: January 28, 2016Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Patent number: 9180133Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: GrantFiled: March 7, 2014Date of Patent: November 10, 2015Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Publication number: 20150174140Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: ApplicationFiled: March 2, 2015Publication date: June 25, 2015Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Publication number: 20150018325Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse.Type: ApplicationFiled: September 29, 2014Publication date: January 15, 2015Inventors: Andre Ulmann, Henri Camille Mathe, Erin Gainer, Diana Blithe
-
Publication number: 20140187525Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Applicants: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, LABORATOIRE HRA-PHARMAInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Patent number: 8722653Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: GrantFiled: September 19, 2012Date of Patent: May 13, 2014Assignees: Laboratoire HRA-Pharma, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Publication number: 20130045959Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse.Type: ApplicationFiled: December 3, 2010Publication date: February 21, 2013Inventors: Andre Ulmann, Henri Camille Mathe, Erin Gainer, Diana Blithe
-
Patent number: 8299050Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: GrantFiled: January 29, 2008Date of Patent: October 30, 2012Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Lynnette Nieman, André Ulmann, Diana Blithe, Erin Gainer
-
Publication number: 20090192130Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: January 29, 2008Publication date: July 30, 2009Applicant: HRA PHARMAInventors: Lynnette NIEMAN, Andre ULMANN, Diana BLITHE, Erin GAINER
-
Patent number: 5445968Abstract: The present invention relates to the purification of the human chorionic gonadotropin .beta.-core molecule which can then be used as the antigen in the preparation of antibodies to the .beta.-core molecule. The combination of the purified .beta.-core molecule and the antibodies can be used in an immunoassay kit to measure .beta.-core molecules in the presence of structurally similar molecules, i.e., hCG, LH, hCG.beta.-subunit and LH.beta.-subunit. Measurement of the .beta.-core molecule is particularly useful in testing for pregnancy and many malignancies.Type: GrantFiled: November 12, 1991Date of Patent: August 29, 1995Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Diana Blithe, Robert E. Wehmann, Bruce C. Nisula